/HOOK

HOOK Stock - HOOKIPA Pharma Inc.

Q: What is the analyst price target for HOOK?

Analyst price target information is not currently available for HOOK.

Q: What is HOOK's market cap?

Market capitalization information is not currently available for HOOK.

Healthcare|Biotechnology|OTC

$0.88-1.79%

$0.02 (-1.79%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+240.9%upside

Target: $3.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HOOK

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.90

52W High$2.80

52W Low$0.72

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$43.95M	$20.13M	$14.25M	$18.45M	$19.58M
Gross Profit	$41.19M	$16.58M	$10.65M	$13.81M	$-33,549,000
Gross Margin	93.7%	82.4%	74.7%	74.8%	-171.3%
Operating Income	$-51,455,000	$-97,694,000	$-73,155,000	$-81,674,000	$-53,285,000
Net Income	$-43,503,000	$-81,580,000	$-64,915,000	$-75,665,000	$-44,082,000
Net Margin	-99.0%	-405.3%	-455.6%	-410.2%	-225.1%
EPS	$-3.47	$-8.63	$-9.91	$-23.04	$-16.93

Company Overview

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

Sell / Underperform

50%

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$17

Average Target

↑ 1812.9% Upside

Now

Low

$17

Average

$48

High

Based on 3 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 20th 2024	RBC Capital Mkts	Downgrade	Sector Perform	$2← $48
November 15th 2024	RBC Capital Mkts	Reiterated	Outperform	$48← $50
December 2nd 2022	BofA Securities	Downgrade	Underperform	$0.5

Earnings History & Surprises

HOOK

Beat Rate

39%

Last 18 quarters

Avg Surprise

-26.2%

EPS vs Estimate

Beats / Misses

7/10

1 met exactly

Latest EPS

$0.09

Q4 2025

EPS Surprise History

Q1 24

+45.0%

$-1.10vs$-2.00

Q2 24

+200.0%

$1.20vs$-1.20

Q3 24

-5.6%

$-1.52vs$-1.44

Q4 24

+14.1%

$-1.10vs$-1.28

Q1 25

-378.0%

$-1.96vs$-0.41

Q2 25

-101.6%

$-1.23vs$-0.61

Q3 25

-137.5%

$-1.52vs$-0.64

Q4 25

+114.8%

$0.09vs$-0.61

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 13, 2026	—	—	—	—
Q1 2026	Feb 26, 2026	—	—	—	—
Q4 2025	Nov 14, 2025	$-0.61	$0.09	+114.8%	✓ BEAT
Q3 2025	Aug 14, 2025	$-0.64	$-1.52	-137.5%	✗ MISS
Q2 2025	May 15, 2025	$-0.61	$-1.23	-101.6%	✗ MISS
Q1 2025	Feb 27, 2025	$-0.41	$-1.96	-378.0%	✗ MISS
Q4 2024	Nov 14, 2024	$-1.28	$-1.10	+14.1%	✓ BEAT
Q3 2024	Aug 8, 2024	$-1.44	$-1.52	-5.6%	✗ MISS
Q2 2024	May 9, 2024	$-1.20	$1.20	+200.0%	✓ BEAT
Q1 2024	Mar 22, 2024	$-2.00	$-1.10	+45.0%	✓ BEAT
Q4 2023	Nov 9, 2023	$-2.30	$-1.70	+26.1%	✓ BEAT
Q3 2023	Aug 10, 2023	$-2.10	$-2.20	-4.8%	✗ MISS
Q2 2023	May 11, 2023	$-2.40	$-2.70	-12.5%	✗ MISS
Q1 2023	Mar 15, 2023	$-1.80	$-1.70	+5.6%	✓ BEAT
Q4 2022	Nov 14, 2022	$-2.40	$-2.50	-4.2%	✗ MISS
Q3 2022	Aug 11, 2022	$-3.60	$-2.30	+36.1%	✓ BEAT
Q2 2022	May 16, 2022	$-1.20	$-4.00	-233.3%	✗ MISS
Q1 2022	Mar 24, 2022	$-5.30	$-6.50	-22.6%	✗ MISS
Q4 2021	Nov 10, 2021	$-5.40	$-6.10	-13.0%	✗ MISS
Q3 2021	Aug 12, 2021	$-5.20	$-5.20	0.0%	= MET